CD4 and infection: ART probably had little effect on the evolutionary dynamics of SPVL in Uganda because it only became available in 2004 and is initiated at relatively late stage infection (CD4 < 250 cells/mm3 from 2004 to January 2011, and at < 350 cells/mm3 from February, 2011 to the time of writing, August 2016).